Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

ABSTRACT:

Purpose

Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued.

Patients and methods

Patients with advanced melanoma (N = 107) enrolled between 2008 and 2012 received intravenous nivolumab in an outpatient setting every 2 weeks for up to 96 weeks and were observed for overall survival, long-term safety, and response duration after treatment discontinuation.

Results

Median overall survival in nivolumab-treated patients (62% with two

SUBMITTER: Topalian SL 

PROVIDER: S-EPMC4811023 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature